Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive trimetazidine for bipolar depression
ACTRN12622000474752Phase 3Recruiting
- Sponsor
- Deakin University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Adjunctive trimetazidine with Adjunctive placebo (2 arms). Primary endpoint: Change in depressive symptom severity. Started Apr 2025; status: recruiting.
02
Drugs
trimetazidine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on ACTRN12622000474752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000474752.